EXACT Therapeutics AS - Minutes from extraordinary general meeting on 13 March 2026

13 Mar 2026 16:28 CET

Oslo, 13 March 2026: Reference is made to the stock exchange announcements on 27
February 2026 regarding the exercise of warrants and the extraordinary general
meeting to issue the new shares pursuant to the warrants exercise.

The extraordinary general meeting was held today, on 13 March 2026, and all
proposals on the agenda were adopted as proposed by the board.

Following issuance of the new shares and exercise of the warrants, the company's
share capital will be NOK 446,176.244, divided into 111,544,061 shares, each
with a nominal value of NOK 0.004.

Please find enclosed the minutes of the meeting including appendices. The
minutes will also be available on the company website: www.exact-tx.com

For more information, please contact:
Per Walday,
CEO
Email per.walday@exact-tx.com

John M. Edminson,
CFO
Email: john.edminson@exact-tx.com

About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further
information may be found here: www.exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site

668333_20260313_EXACT_Therapeutics_-_EGM_minutes.pdf